Pfizer to Acquire Trillium Therapeutics Inc
Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Q2 2021 hedge fund letters, conferences and more Expands innovative pipeline, potentially enhancing growth in 2026-2030 and beyond Pfizer to host analyst and investor call at 10:00 a.m. ET today with Pfizer Oncology executives Pfizer To Acquire Trillium TherapeuticsNEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Pfizer Inc (NYSE:PFE) and Trillium Therapeutics Inc (NASDAQ:TRIL) today announced that the companies have entere...